95 results about "Immunoglobulin G" patented technology

The invention provides a test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of the test strip, and belongs to the technical field of biochemical detection. The test strip comprises a bottom plate, a sample pad, a combination pad, a detection pad and a water absorption pad, the two ends of the detection pad are in lap joint with the combination pad and the water absorption pad respectively, the detection pad is located on the lower portion, the sample pad is in lap joint with the combination pad, and the combination pad is located on the lower portion; a detection line and a quality control line are arranged on the detection pad, the detection line is arranged on one side close to the combination pad, and the quality control line is arranged on one side close to the water absorption pad; the detection pad is coated with a MoS2 nanosheet, the combination pad is coated with a penicillin binding protein 2a polyclonal antibody labeled by horse radish peroxidase, and the detection line is coated with a penicillin binding protein 2a monoclonal antibody; the quality control line is coated with goat anti-rabbit IgG (immunoglobulin G). The kit is high in sensitivity and wide in linear range, has good specificity, repeatability and stability, and can effectively detect MRSA in a clinical sample.

The invention discloses a method for constructing an N-glycosylation spectrum type biological age evaluation model based on plasma immunoglobulin G and application of the biological age evaluation model. Based on a glycosyl quantitative result, a clinical biochemical detection index, a lifestyle measurement index, a multi-dimensional health score and the like, a glycosyl metabolic index, a glycosyl inflammation index, a glycosyl cardiovascular index, a glycosyl stroke index, a glycosyl liver index and a glycosyl kidney index are fitted. And inputting the obtained different glycosyl data into the model, and speculating the aging process and health risk of each organ system of the detected person according to the risk threshold in the early-stage crowd. The method can predict a'glycosyl biological age system 'which can reflect health level and disease risk better than'calendar age', has individual specificity, is very sensitive to change of inflammatory response in vivo, is relatively stable in a short time, can be used as an index for early detection and screening of senescence, and can be used as an index for early detection and screening of senescence. And thus, effective reference is provided for individualized health suggestions of the detected personnel.

A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection delivery device. The method can be used in the treatment of a disease, such as an immunodeficiency.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.

The invention relates to an aptamer specifically combined with beta-lactoglobulin and application of the aptamer, and belongs to the technical field of biological detection. According to the aptamer and the preparation method thereof, a binding domain base, participating in recognition, of the aptamer is predicted through molecular docking firstly, then the binding domain base is subjected to directional mutation, the aptamer with the recognition performance improved is obtained, the affinity of the aptamer to beta-lactoglobulin is 10.6 nM, and the aptamer has no recognition capacity on alpha-lactalbumin, casein, bovine serum albumin, immune globulin G, lactose and the like and can be used for preparing the aptamer with the recognition performance improved. Therefore, the aptamer disclosed by the invention has good sensitivity and specificity on the beta-lactoglobulin. On the basis, a fluorescence polarization method is directly constructed by utilizing the characteristic that the beta-lactoglobulin is a biomacromolecule, when the beta-lactoglobulin exists, an aptamer marked by a fluorophore FAM recognizes the beta-lactoglobulin to form an aptamer beta-lactoglobulin compound, and the fluorescence polarization value is relatively large, so that the beta-lactoglobulin compound can be used for identifying the beta-lactoglobulin. Therefore, the specific detection of the low-concentration beta-lactoglobulin is realized.

The invention relates to the technical field of biological detection, in particular to a sample diluent as well as a preparation method and application thereof. The sample diluent comprises a dilution component, and the dilution component comprises the following raw materials in percentage by mass: 0.005%-0.02% of thermally denatured immunoglobulin G, 0.5%-2.0% of a protein protective agent, 0.5%-1.5% of a metal ion chelating agent, 0.1%-0.5% of an ampholytic surfactant and 0.5%-2.0% of a sugar alcohol compound. According to the sample diluent, through the interaction of all the components, the ability of the sample diluent to reduce the matrix effect of serum and plasma samples can be remarkably improved, so that the interference of non-specific reaction and matrix effect of serum and plasma on the detection process is reduced, and the accuracy of serum and plasma sample detection can be improved; and a more reliable and accurate experiment result can be obtained.

Described herein are bifunctional compounds for removing macrophage migration inhibitory factor (MIF) or immunoglobulin G (IgG). Further described herein are pharmaceutical compositions comprising these bifunctional compounds. Further described herein are methods for treating pathologies and / or conditions with said compounds or compositions. The pathologies and / or conditions are mediated through MIF / IgG or where MIF / IgG is a contributing factor in the development and perpetuation of diseases and / or conditions, such as autoimmune diseases and cancers, among others. TIFF2025509736000504.tif99145

Provided is a method of treating rheumatoid arthritis, comprising administering to a subject in need of such treatment a therapeutically effective amount of a degrader of immunoglobulin G and an anti-arthritis agent. Also provided is a pharmaceutical composition comprising a degrader of immunoglobulin G and an anti-arthritis agent.

The present application relates to the field of livestock breeding technology, and discloses a molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma and application thereof.The molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma is the 251th nucleotide in SEQ ID NO:1, and the polymorphic form is G or A.The SNP molecular marker related to the level of natural immunoglobulin G antibody in chicken plasma provided by the present application can be used to select the level of natural immunoglobulin G antibody in chicken plasma at the genetic level, directly screen the level of natural immunoglobulin G antibody in chicken plasma from the root source, accurately grasp the genetic information, effectively avoid the disadvantages of traditional methods, significantly improve the efficiency and accuracy of selection, and can be applied to chicken breeding practice on a large scale, and promote the development of the industry.

The invention discloses an application of a biomarker in evaluating the risk of progressing from autoimmune hepatitis to cirrhosis. The biomarker comprises immune globulin G, and / or an antinuclear antibody, and / or aspartate aminotransferase and alanine aminotransferase. Independent predictive factor indexes of the liver cirrhosis risk of an autoimmune hepatitis patient in the biomarker are as follows: an antinuclear antibody ANA index: log2ANA is greater than or equal to 1.62; the AAR index of the ratio of aspartate aminotransferase to alanine aminotransferase is as follows: AAR is greater than or equal to 1.62; the immune globulin G, namely the IgG index, is greater than or equal to 30.3 g / L. The problems that in the prior art, an AIH risk model does not take cirrhosis as the outcome, visual presentation is lacked, prediction efficiency is insufficient, and clinical early-stage accurate risk layering and diagnosis and treatment decision requirements are difficult to meet are solved.

This invention provides a bovine colostrum IgG nutritional supplement gummies and their preparation method, belonging to the field of functional food technology. The bovine colostrum IgG nutritional supplement gummies of this invention, through precise formulation of specific components, effectively improve the dispersion uniformity of whole-fat bovine colostrum freeze-dried powder in the gummy base, significantly retaining the activity of immunoglobulin G, giving the product a stable texture and good taste; further, combined with a special process adapted to the formula, high yield and high raw material utilization are achieved in industrial production. This product combines immune nutritional supplementation with convenient consumption, making it suitable for people of all ages and possessing good market application prospects.

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The present disclosure relates to a method for separating and obtaining a target protein-enriched solution, such as immunoglobulin G (IgG), and a plurality of target protein-depleted fractions from a protein mixture, such as plasma or fractions thereof, using continuous chromatography. The present disclosure also relates to a continuous chromatography system for separating a target protein from a protein mixture, a formulation of its purified product and uses.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

The present invention belongs to the field of optical sensing technology and discloses an optical sensor based on a rare-earth-doped microbubble cavity. To predict concentration, the rare-earth-doped microbubble cavity is first pumped with a pump source laser. An immunoglobulin G solution to be tested is then injected into the microfluidic channel of the rare-earth-doped microbubble cavity, and the resulting signal laser spectrum is recorded. The signal laser power is then compared with a standard curve that correlates concentration and signal laser power. The concentration corresponding to the same signal laser power is found, and the concentration of the immunoglobulin G solution to be tested is thus determined. By utilizing the active cavity structure of the rare-earth-doped microbubble cavity to detect biomolecules, the present invention enables the realization of a high-precision biosensor capable of predicting both the concentration of an immunoglobulin solution and the occurrence of specific binding between multiple immunoglobulins.

Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.

The invention discloses a creatine kinase isoenzyme detection reagent, and belongs to the technical field of biological detection. The creatine kinase isoenzyme detection reagent comprises a reagent A and a reagent B, the reagent A is prepared from 30 to 60mM of a Hepes buffer solution, 0.2 to 0.5 g / L of mouse IgG (Immunoglobulin G), 1 to 5g / L of TritonX-100, 0.4 to 0.8 g / L of a stabilizer and 1 to 2g / L of a template separating agent; the reagent B is prepared from 30 to 60 mM of Hepes buffer solution, 1 to 3 g / L of sealing agent, 1 to 5 g / L of stabilizing agent and 1 to 3 g / L of polystyrene latex microsphere coupled with antibody. The template separating agent is added into the reagent A, so that active sites of CK-BB or CK-MM can be effectively hindered, the influence on CK-MB is reduced by selecting the reagent, and combination of CK-BB or CK-MM and a template is facilitated; after the polystyrene latex microspheres added with the magnetic coupling antibody in the reagent B are combined with the CK-MM, the content of an object to be detected is determined according to the change of the absorbance value of a sample, and the creatine kinase isoenzyme detection reagent is high in accuracy.

The utility model discloses a kit for ultra-sensitive detection of a PLA2R-IgG (Immunoglobulin G) antibody. The kit comprises a kit body, and a box cover door is arranged on the front side of the kit body and hinged to one end of the kit body; a foldable handle is arranged on the box body; rotary connecting pieces are fixedly mounted on the outer surfaces of the left and right sides of the box body; the two ends of the foldable handle are rotatably and movably connected with the box body through rotary connecting pieces respectively; a sliding rail with a groove is fixedly mounted at each of the upper part and the bottom part of the inner walls of the left side and the right side of the box body, and the sliding rail at the upper part is connected with the transverse box; a rectangular positioning groove capable of placing a polystyrene pore plate is formed in the transverse box; the bottom slide rail is connected with the bottom box; and the bottom box is provided with a circular positioning hole groove for placing a reagent bottle for containing a reagent or a standard substance and a rectangular positioning hole groove for placing an ice bag. By arranging the sliding rail, the transverse box, the bottom box, the positioning hole groove, the foldable handle and the like, the purpose of improving convenience and stability in the storage and transfer process is achieved.

The present invention relates to a multivalent, preferably bivalent, antibody complex, more preferably a diabody, i.e. a bivalent scFv, capable of recognizing and binding the human protein CD99, a composition comprising said complex and the use thereof for diagnostic purposes and / or for the treatment and / or the follow-up of leukaemias and / or myelodysplastic syndromes. Furthermore, the present invention relates to antibodies, preferably monoclonal, of the immunoglobulins G group type capable of recognizing and binding the human protein CD99, a composition comprising said immunoglobulins and the medical use thereof, in particular for the treatment and / or the follow-up of cancer, preferably solid tumours that express CD99 and / or leukaemias and / or myelodysplastic syndromes.

The invention discloses a kit for latex immunoturbidimetric determination of urine immunoglobulin G, and relates to the field of biological detection technology. The kit includes R1 reagent and R2 reagent; the R1 reagent includes 10-200mM tris(hydroxymethyl)aminomethane, 1-10g / L bovine serum albumin, 10-50g / L reaction enhancer, 0.1-10mL / L preservative, 100-300mM NaCl, 2-6g / L surfactant; the R2 reagent includes 10-200mM tris(hydroxymethyl)aminomethane, 100-300mM NaCl, 1-5g / L antibody-coupled latex particles, 1-5g / L glycerol, 5-10g / L methyl-β-cyclodextrin, 1-10g / L bovine serum albumin, 2-6g / L surfactant and 0.1-10mL / L preservative. The kit of the present invention has good repeatability and stability.

The invention discloses a double-antibody sandwich ELISA kit for detecting ENTV and JSRV and application of the double-antibody sandwich ELISA kit, and belongs to the technical field of biology. The double-antibody sandwich ELISA kit contains an ELISA plate coated with a monoclonal antibody for resisting goat endemic intranasal tumor virus p27 protein, a polyclonal antibody for resisting goat endemic intranasal tumor virus p27 protein and HRP (horse radish peroxidase) labeled goat anti-rabbit IgG (immunoglobulin G). Wherein the monoclonal antibody for resisting the goat endemic intranasal tumor virus p27 protein is secreted by a hybridoma cell strain ENTV-2C3, the hybridoma cell strain ENTV-2C3 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: C 2024412. The double-antibody sandwich ELISA kit established by the invention has the characteristics of high detection sensitivity and good specificity, can be used for detecting goat endemic intranasal tumor virus and sheep lung adenoma retrovirus, and provides a technical means for prevention and control of goat endemic intranasal tumor and sheep lung adenoma.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The present application belongs to the field of clinical medicine, and particularly relates to a method for establishing an esophageal cancer auxiliary diagnosis model based on immunoglobulin G Fc segment N-glycosyl in serum and application thereof. The biomarker on which the esophageal cancer auxiliary diagnosis model provided by the present application is based is immunoglobulin G Fc segment N-glycosyl GP10, GP11, GP14, GP17 and GP23. The diagnosis model provided by the present application is constructed based on the level of five initial immunoglobulin G N-glycosyl in serum, and has the advantages of simplicity, convenient calculation and easy judgment. The model has high accuracy, high sensitivity and strong specificity for esophageal cancer diagnosis, and is much higher than the diagnosis of the conventional cancer markers CEA and CA199. The esophageal cancer diagnosis model constructed by the present application provides an effective, reliable and convenient method for the clinical diagnosis of gastrointestinal health, and has good auxiliary diagnosis value for gastrointestinal health.

To provide methods and compositions (including compositions of engineered / synthetic binding agents) for enhancing agglutination, enchainment and / or muco-trapping of a target, i.e., reducing the fraction of target entities that could permeate through mucus, including pathogens and sperm.SOLUTION: Provided are synthetic binding agents for reducing the fraction of targets that can permeate through mucus and / or freely divide, and methods of reducing mucosal permeation and / or free division of a target using these synthetic binding agents. The synthetic binding agent comprises a human or humanized Immunoglobulin G (IgG) having a pair of Fab domains, and enhances agglutination of the target in the subject's mucus to reduce the mobility of the target to less than about 50% relative to its native mobility in mucus.SELECTED DRAWING: Figure 1A

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.

The invention relates to a preparation method of an EB (Epstein-Barr) virus capsid antigen-magnetic bead complex, which comprises the following steps: adding 0.5-2M of PB buffer solution and EB virus capsid antigen into magnetic beads, uniformly mixing at 15-30 DEG C, and standing for 2-3 hours; wherein the EB virus capsid antigen is a VCA-P18 antigen and / or a VCA-P23 antigen; adding a confining liquid, and uniformly mixing at 15-37 DEG C for 1-3 hours; removing supernate, and adding a magnetic bead diluent for resuspension; the magnetic bead diluent comprises about 0.1 M of a Tris-HCl buffer solution, Casein of which the mass volume ratio is 0.2%-1.0%, MAK33 of which the mass volume ratio is (10-30) [mu] g / mL, and TW20 of which the mass volume ratio is 0.3%-0.8%.

The present disclosure is related to chimeric antigen receptors (CARs) comprising Immunoglobulin G (IgG) derived spacers, e.g., a human IgG hinge and a human IgG Fc derived CAR spacer. IgGl derived spacers confer improved properties to the CARs, e.g., increased cytokine release with respect to CARs not comprising IgG derived spacers. Also provided are cells expressing CARs comprising IgG derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer.

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and / or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

A dental paste or gel is provided comprising a composition having: at least 2 to 4 % w / w agar; at least 62 to 95 % w / w glycerol; and at least 0.03 to 3 % w / w epithelial-adhering protein complex. The e

Methods are provided for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-parvo B19 immunoglobulin G. The methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-parvo B19 immunoglobulin G are also provided. Methods for treating parvo B19 infections by administration of plasma-derived IgG compositions highly enriched for anti-parvo B19 immunoglobulin G are also provided.